Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 800 shares, a decrease of 50.0% from the February 13th total of 1,600 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 559,900 shares, the days-to-cover ratio is presently 0.0 days.

Daiichi Sankyo Price Performance

Shares of DSNKY opened at $23.12 on Friday. The company has a market capitalization of $44.12 billion and a price-to-earnings ratio of 26.88. Daiichi Sankyo has a fifty-two week low of $22.47 and a fifty-two week high of $42.48. The firm has a 50-day simple moving average of $25.34 and a 200-day simple moving average of $30.01. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.11 and a current ratio of 2.77.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its earnings results on Friday, January 31st. The company reported $0.22 earnings per share (EPS) for the quarter. Daiichi Sankyo had a net margin of 13.62% and a return on equity of 14.53%. On average, equities research analysts anticipate that Daiichi Sankyo will post 0.73 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.